Menu

Generating Cardiac Precursor Cells

Researchers derive cardiac precursors to form cardiac muscle, endothelial, and smooth muscle cells in mice.

Jun 1, 2016
Kerry Grens

TRANSFORMED: Mouse heart muscle cells derived from induced cardiovascular progenitor cellsYU ZHANG

EDITOR'S CHOICE IN CELL & MOLECULAR BIOLOGY

The paper
Y. Zhang et al., “Expandable cardiovascular progenitor cells reprogrammed from fibroblasts,” Cell Stem Cell, 18:368-81, 2016.

The trials
To repair cardiac damage after a heart attack, numerous clinical studies have experimented with injecting a variety of potentially therapeutic cells into patients, but very little of the introduced material sticks around. It’s thought these cells act indirectly—via paracrine mechanisms—to regrow heart muscle, and the benefits have been modest at best. So Sheng Ding of the Gladstone Institute of Cardiovascular Disease and the University of California, San Francisco, has been working on another idea: produce progenitor cells that will grow into new heart tissue.

Precursors
Ding’s team succeeded in generating easy-to-grow progenitor cells—either from induced pluripotent stem cells or directly from fibroblasts—that could become any of three lineages in the heart: cardiomyocytes, smooth muscle, or endothelium. Injecting these cardiac precursors into mice with infarcted hearts staved off declines in heart function.

Recipes
Lab-grown cardiac precursors have been produced before, says Christine Mummery of Leiden University Medical Center, but they’ve been difficult to expand or have required an activated oncogene to grow. In Ding’s study, a cocktail of transcription factors did the job, and the cells proliferated readily. “It’s amazing they were able to get so many [cardiomyocyte] cells” from the precursors, says Stanford University’s Joseph Wu. “I think people will be encouraged there are independent ways of making cardiac progenitors that can expand,” Mummery says.

Next steps
Wu calls the findings “exciting,” especially the production of precursors directly from fibroblasts. He adds that more research is needed to replicate the results and see how the cells behave in humans. Ding says his group is now focused on optimizing the protocol for human cells.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.